Tm Bioscience granted U.S. patent
- 3rd Patent extends Tm's position in DNA diagnostic and biochip
technologies -
TORONTO, May 20 /CNW/ - VSE - TMC Tm Bioscience, a leader in the
development of DNA (nucleic acids) technologies, is pleased to announce that
U.S. Patent No. 5902724 has been granted for Tm's signal amplification system.
The patent covers the Company's universal signal amplification system which
improves the detection sensitivity of DNA-based and other medical diagnostic
tests.
Current DNA tests often lack sufficient sensitivity or require complex
and expensive methodology to detect mutations or pathogens like the AIDS
virus. Tm's signal-amplifier provides a simple and cost-effective solution to
this problem. Using this system the Company has demonstrated up to a
100,000-fold improvement in the sensitivity of specific tests and believes
that this can be extended even further.
''This is a very valuable and timely event as we continue to
commercialize our technologies,'' said Dr. Richard Janeczko, V.P. Business
Development. ''Our signal amplification system has broad-based applications
and directly addresses key issues of cost, complexity and sensitivity in many
DNA tests. It is the third patent issued to us recently and significantly
strengthens our position in the DNA diagnostic and biochip markets. It will be
pivotal in advancing our commercialization strategy of licensing our
technologies to the major manufacturers of these types of tests.''
The Company's Annual General Meeting will be held in Toronto, Ontario on
Tuesday June 1, 1999 at 4:00pm at the Toronto Board of Trade.
Tm Bioscience is an emerging Canadian biotechnology company developing
and commercializing proprietary DNA based technologies for application in
biochips, diagnostics and genomic analysis. The Company offers pharmaceutical
and biotechnology companies the ability to develop novel nucleic acid-based
products for medical and research applications. Additional information about
Tm Bioscience can be found at www.tmbioscience.com.
Tm Bioscience trades on the Vancouver Stock Exchange under the symbol TMC
and has approximately 69 million shares outstanding.
THE VANCOUVER STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT
RESPONSIBILITY FOR THE ADEQUACY AND ACCURACY OF THIS NEWS RELEASE.
-0- 05/20/1999
For further information: Don MacAdam, President & CEO, (416) 593-4323, (416) 593-1066 fax, dmacadam@tmbioscience.com; Jay Hussey, Investor and Media Inquiries, (416) 815-0700, ext. 225, (416) 815-0080 fax; jhussey@equicomgroup.com
|
